<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00768716</url>
  </required_header>
  <id_info>
    <org_study_id>8600</org_study_id>
    <secondary_id>R01GM061834</secondary_id>
    <secondary_id>R01GM102130</secondary_id>
    <nct_id>NCT00768716</nct_id>
  </id_info>
  <brief_title>Effect of Race/Ethnicity and Genes on Acetaminophen Pharmacokinetics</brief_title>
  <official_title>Effect of Race/Ethnicity and Genes on Acetaminophen Pharmacokinetics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tufts University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of General Medical Sciences (NIGMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Tufts University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although acetaminophen is the most commonly used nonprescription drug in the USA, little is
      known regarding the influence of genes and race/ethnicity on acetaminophen disposition. The
      investigators long-term goal is to understand the causes of differences in acetaminophen
      disposition between people that are the result of genetic variation and ethnicity and may
      predispose individuals to a higher risk of acetaminophen hepatotoxicity. The aim of this
      particular study is to measure the rate of elimination of acetaminophen via the 3 main
      pathways (glucuronidation, sulfation and oxidation) in self-identified White-Americans
      (n=100) and African-Americans (n=100). These rates will then be correlated with selected
      genetic polymorphisms in genes encoding enzymes involved in acetaminophen metabolism. Two
      main hypotheses will be tested: 1. African-Americans eliminate acetaminophen more rapidly by
      glucuronidation than do White-Americans. 2. Elimination via glucuronidation, sulfation, and
      oxidation in subjects will be significantly correlated with the presence of polymorphisms in
      the UGT1A6, SULT1A1, and CYP2E1 genes, respectively.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2008</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acetaminophen Plasma Clearance Association With Race/Ethnicity</measure>
    <time_frame>2 days</time_frame>
    <description>Plasma total clearance of acetaminophen in plasma measured by HPLC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acetaminophen Glucuronidation Partial Clearance Association With Race/Ethnicity</measure>
    <time_frame>2 days</time_frame>
    <description>Acetaminophen glucuronidation partial clearance determined from plasma clearance and urinary metabolite excretion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acetaminophen Sulfation Partial Clearance Association With Race/Ethnicity</measure>
    <time_frame>2 days</time_frame>
    <description>Acetaminophen sulfation partial clearance determined from plasma clearance and urinary metabolite excretion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acetaminophen Oxidation Partial Clearance Association With Race/Ethnicity</measure>
    <time_frame>2 days</time_frame>
    <description>Acetaminophen oxidation partial clearance determined from plasma clearance and urinary metabolite excretion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acetaminophen Plasma Clearance Association With UGT2B15 Genotype</measure>
    <time_frame>2 days</time_frame>
    <description>The association of UGT2B15 genotype with acetaminophen total clearance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acetaminophen Glucuronidation Partial Clearance Association With UGT2B15 Genotype</measure>
    <time_frame>2 days</time_frame>
    <description>The association of acetaminophen glucuronidation partial clearance with UGT2B15 genotype</description>
  </primary_outcome>
  <primary_outcome>
    <measure>APAP Plasma Adduct Association With UGT2B15 Genotype</measure>
    <time_frame>2 days</time_frame>
    <description>The association of UGT2B15 genotype with APAP plasma adduct concentrations</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Pain</condition>
  <condition>Fever</condition>
  <condition>Hepatotoxicity</condition>
  <arm_group>
    <arm_group_label>White subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 x 500 mg acetaminophen by mouth once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Black subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 x 500 mg acetaminophen by mouth once</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <description>2 x 500 mg by mouth once</description>
    <arm_group_label>Black subjects</arm_group_label>
    <arm_group_label>White subjects</arm_group_label>
    <other_name>Tylenol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  self-declared white/Caucasian

          -  self-declared African-American

          -  active

          -  ambulatory

          -  no evidence of medical disease

        Exclusion Criteria:

          -  alcohol use of 3 or more drinks per day

          -  HIV or hepatitis (B or C) infection

          -  isoniazid

          -  disulfiram

          -  phenobarbital

          -  phenytoin

          -  carbamazepine

          -  rifampicin

          -  valproic acid

          -  probenecid

          -  St. John's Wort
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael H Court, BVSc, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tufts University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tufts Clinical Pharmacology Study Unit</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Krishnaswamy S, Hao Q, Al-Rohaimi A, Hesse LM, von Moltke LL, Greenblatt DJ, Court MH. UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: I. Identification of polymorphisms in the 5'-regulatory and exon 1 regions, and association with human liver UGT1A6 gene expression and glucuronidation. J Pharmacol Exp Ther. 2005 Jun;313(3):1331-9. Epub 2005 Mar 10.</citation>
    <PMID>15761114</PMID>
  </reference>
  <reference>
    <citation>Krishnaswamy S, Hao Q, Al-Rohaimi A, Hesse LM, von Moltke LL, Greenblatt DJ, Court MH. UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). J Pharmacol Exp Ther. 2005 Jun;313(3):1340-6. Epub 2005 Mar 10.</citation>
    <PMID>15761113</PMID>
  </reference>
  <reference>
    <citation>Court MH, Duan SX, von Moltke LL, Greenblatt DJ, Patten CJ, Miners JO, Mackenzie PI. Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. J Pharmacol Exp Ther. 2001 Dec;299(3):998-1006.</citation>
    <PMID>11714888</PMID>
  </reference>
  <reference>
    <citation>Volak LP, Hanley MJ, Masse G, Hazarika S, Harmatz JS, Badmaev V, Majeed M, Greenblatt DJ, Court MH. Effect of a herbal extract containing curcumin and piperine on midazolam, flurbiprofen and paracetamol (acetaminophen) pharmacokinetics in healthy volunteers. Br J Clin Pharmacol. 2013 Feb;75(2):450-62. doi: 10.1111/j.1365-2125.2012.04364.x.</citation>
    <PMID>22725836</PMID>
  </reference>
  <reference>
    <citation>Court MH, Freytsis M, Wang X, Peter I, Guillemette C, Hazarika S, Duan SX, Greenblatt DJ, Lee WM; Acute Liver Failure Study Group. The UDP-glucuronosyltransferase (UGT) 1A polymorphism c.2042C&gt;G (rs8330) is associated with increased human liver acetaminophen glucuronidation, increased UGT1A exon 5a/5b splice variant mRNA ratio, and decreased risk of unintentional acetaminophen-induced acute liver failure. J Pharmacol Exp Ther. 2013 May;345(2):297-307. doi: 10.1124/jpet.112.202010. Epub 2013 Feb 13.</citation>
    <PMID>23408116</PMID>
  </reference>
  <reference>
    <citation>Court MH, Peter I, Hazarika S, Vasiadi M, Greenblatt DJ, Lee WM; Acute Liver Failure Study Group. Candidate gene polymorphisms in patients with acetaminophen-induced acute liver failure. Drug Metab Dispos. 2014 Jan;42(1):28-32. doi: 10.1124/dmd.113.053546. Epub 2013 Oct 8.</citation>
    <PMID>24104197</PMID>
  </reference>
  <reference>
    <citation>Zhao Y, Harmatz JS, Epstein CR, Nakagawa Y, Kurosaki C, Nakamura T, Kadota T, Giesing D, Court MH, Greenblatt DJ. Favipiravir inhibits acetaminophen sulfate formation but minimally affects systemic pharmacokinetics of acetaminophen. Br J Clin Pharmacol. 2015 Nov;80(5):1076-85. doi: 10.1111/bcp.12644. Epub 2015 Jun 8.</citation>
    <PMID>25808818</PMID>
  </reference>
  <reference>
    <citation>Papageorgiou I, Freytsis M, Court MH. Transcriptome association analysis identifies miR-375 as a major determinant of variable acetaminophen glucuronidation by human liver. Biochem Pharmacol. 2016 Oct 1;117:78-87. doi: 10.1016/j.bcp.2016.08.014. Epub 2016 Aug 13.</citation>
    <PMID>27531059</PMID>
  </reference>
  <reference>
    <citation>Papageorgiou I, Court MH. Identification and validation of microRNAs directly regulating the UDP-glucuronosyltransferase 1A subfamily enzymes by a functional genomics approach. Biochem Pharmacol. 2017 Aug 1;137:93-106. doi: 10.1016/j.bcp.2017.04.017. Epub 2017 Apr 19.</citation>
    <PMID>28433553</PMID>
  </reference>
  <results_reference>
    <citation>Court MH, Zhu Z, Masse G, Duan SX, James LP, Harmatz JS, Greenblatt DJ. Race, Gender, and Genetic Polymorphism Contribute to Variability in Acetaminophen Pharmacokinetics, Metabolism, and Protein-Adduct Concentrations in Healthy African-American and European-American Volunteers. J Pharmacol Exp Ther. 2017 Sep;362(3):431-440. doi: 10.1124/jpet.117.242107. Epub 2017 Jun 29.</citation>
    <PMID>28663312</PMID>
  </results_reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>October 7, 2008</study_first_submitted>
  <study_first_submitted_qc>October 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2008</study_first_posted>
  <results_first_submitted>April 3, 2019</results_first_submitted>
  <results_first_submitted_qc>April 16, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 8, 2019</results_first_posted>
  <last_update_submitted>May 9, 2019</last_update_submitted>
  <last_update_submitted_qc>May 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>White Subjects</title>
          <description>2 x 500 mg acetaminophen by mouth once
Acetaminophen: 2 x 500 mg by mouth once</description>
        </group>
        <group group_id="P2">
          <title>Black Subjects</title>
          <description>2 x 500 mg acetaminophen by mouth once
Acetaminophen: 2 x 500 mg by mouth once</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>White Subjects</title>
          <description>2 x 500 mg acetaminophen by mouth once</description>
        </group>
        <group group_id="B2">
          <title>Black Subjects</title>
          <description>2 x 500 mg acetaminophen by mouth once</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="54"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="95"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Acetaminophen Plasma Clearance Association With Race/Ethnicity</title>
        <description>Plasma total clearance of acetaminophen in plasma measured by HPLC</description>
        <time_frame>2 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>White Subjects</title>
            <description>2 x 500 mg acetaminophen by mouth once</description>
          </group>
          <group group_id="O2">
            <title>Black Subjects</title>
            <description>2 x 500 mg acetaminophen by mouth once</description>
          </group>
        </group_list>
        <measure>
          <title>Acetaminophen Plasma Clearance Association With Race/Ethnicity</title>
          <description>Plasma total clearance of acetaminophen in plasma measured by HPLC</description>
          <units>mL/min/kg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="4.8" upper_limit="6.4"/>
                    <measurement group_id="O2" value="5.9" lower_limit="5.1" upper_limit="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.52</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Acetaminophen Glucuronidation Partial Clearance Association With Race/Ethnicity</title>
        <description>Acetaminophen glucuronidation partial clearance determined from plasma clearance and urinary metabolite excretion</description>
        <time_frame>2 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>White Subjects</title>
            <description>2 x 500 mg acetaminophen by mouth once</description>
          </group>
          <group group_id="O2">
            <title>Black Subjects</title>
            <description>2 x 500 mg acetaminophen by mouth once</description>
          </group>
        </group_list>
        <measure>
          <title>Acetaminophen Glucuronidation Partial Clearance Association With Race/Ethnicity</title>
          <description>Acetaminophen glucuronidation partial clearance determined from plasma clearance and urinary metabolite excretion</description>
          <units>mL/min/kg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="2.3" upper_limit="3.8"/>
                    <measurement group_id="O2" value="3.3" lower_limit="2.4" upper_limit="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.42</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Acetaminophen Sulfation Partial Clearance Association With Race/Ethnicity</title>
        <description>Acetaminophen sulfation partial clearance determined from plasma clearance and urinary metabolite excretion</description>
        <time_frame>2 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>White Subjects</title>
            <description>2 x 500 mg acetaminophen by mouth once</description>
          </group>
          <group group_id="O2">
            <title>Black Subjects</title>
            <description>2 x 500 mg acetaminophen by mouth once</description>
          </group>
        </group_list>
        <measure>
          <title>Acetaminophen Sulfation Partial Clearance Association With Race/Ethnicity</title>
          <description>Acetaminophen sulfation partial clearance determined from plasma clearance and urinary metabolite excretion</description>
          <units>mL/min/kg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="1.1" upper_limit="1.7"/>
                    <measurement group_id="O2" value="1.7" lower_limit="1.3" upper_limit="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.06</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Acetaminophen Oxidation Partial Clearance Association With Race/Ethnicity</title>
        <description>Acetaminophen oxidation partial clearance determined from plasma clearance and urinary metabolite excretion</description>
        <time_frame>2 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>White Subjects</title>
            <description>2 x 500 mg acetaminophen by mouth once</description>
          </group>
          <group group_id="O2">
            <title>Black Subjects</title>
            <description>2 x 500 mg acetaminophen by mouth once</description>
          </group>
        </group_list>
        <measure>
          <title>Acetaminophen Oxidation Partial Clearance Association With Race/Ethnicity</title>
          <description>Acetaminophen oxidation partial clearance determined from plasma clearance and urinary metabolite excretion</description>
          <units>mL/min/kg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="0.65" upper_limit="1.15"/>
                    <measurement group_id="O2" value="0.57" lower_limit="0.49" upper_limit="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Acetaminophen Plasma Clearance Association With UGT2B15 Genotype</title>
        <description>The association of UGT2B15 genotype with acetaminophen total clearance</description>
        <time_frame>2 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>UGT2B15*1/*1</title>
            <description>UGT2B15 genotype</description>
          </group>
          <group group_id="O2">
            <title>UGT2B15*1/*2</title>
            <description>UGT2B15 genotype</description>
          </group>
          <group group_id="O3">
            <title>UGT2B15*2/*2</title>
            <description>UGT2B15 genotype</description>
          </group>
        </group_list>
        <measure>
          <title>Acetaminophen Plasma Clearance Association With UGT2B15 Genotype</title>
          <description>The association of UGT2B15 genotype with acetaminophen total clearance</description>
          <units>mL/min/kg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" lower_limit="5.4" upper_limit="7.7"/>
                    <measurement group_id="O2" value="5.5" lower_limit="4.9" upper_limit="6.5"/>
                    <measurement group_id="O3" value="4.7" lower_limit="4.2" upper_limit="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Acetaminophen Glucuronidation Partial Clearance Association With UGT2B15 Genotype</title>
        <description>The association of acetaminophen glucuronidation partial clearance with UGT2B15 genotype</description>
        <time_frame>2 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>UGT2B15*1/*1</title>
            <description>UGT2B15 genotype</description>
          </group>
          <group group_id="O2">
            <title>UGT2B15*1/*2</title>
            <description>UGT2B15 genotype</description>
          </group>
          <group group_id="O3">
            <title>UGT2B15*2/*2</title>
            <description>UGT2B15 genotype</description>
          </group>
        </group_list>
        <measure>
          <title>Acetaminophen Glucuronidation Partial Clearance Association With UGT2B15 Genotype</title>
          <description>The association of acetaminophen glucuronidation partial clearance with UGT2B15 genotype</description>
          <units>mL/min/kg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="2.7" upper_limit="4.0"/>
                    <measurement group_id="O2" value="2.8" lower_limit="2.2" upper_limit="3.9"/>
                    <measurement group_id="O3" value="2.1" lower_limit="1.4" upper_limit="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>APAP Plasma Adduct Association With UGT2B15 Genotype</title>
        <description>The association of UGT2B15 genotype with APAP plasma adduct concentrations</description>
        <time_frame>2 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>UGT2B15*1/*1</title>
            <description>UGT2B15 genotype</description>
          </group>
          <group group_id="O2">
            <title>UGT2B15*1/*2</title>
            <description>UGT2B15 genotype</description>
          </group>
          <group group_id="O3">
            <title>UGT2B15*2/*2</title>
            <description>UGT2B15 genotype</description>
          </group>
        </group_list>
        <measure>
          <title>APAP Plasma Adduct Association With UGT2B15 Genotype</title>
          <description>The association of UGT2B15 genotype with APAP plasma adduct concentrations</description>
          <units>mL/min/kg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="11" upper_limit="23"/>
                    <measurement group_id="O2" value="19" lower_limit="13" upper_limit="26"/>
                    <measurement group_id="O3" value="27" lower_limit="21" upper_limit="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>White Subjects</title>
          <description>2 x 500 mg acetaminophen by mouth once</description>
        </group>
        <group group_id="E2">
          <title>Black Subjects</title>
          <description>2 x 500 mg acetaminophen by mouth once</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Michael H. Court</name_or_title>
      <organization>Washington State University</organization>
      <phone>5093350817</phone>
      <email>michael.court@wsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

